## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Applicat	ion of:				
Dario NERI et al.			Examiner: Virginia Allen PORTNER			
Serial No.: 10/821,930			Group Art Unit: 1645			
Filed:	April 1	2, 2004	Confirmation No: 3681			
Title:	CONT	FIC BINDING MOLECULES FOR STAINING THEM AND THERAPEU TAINING THEM AND THERAPEU TMENT OF ANGIOGENESIS				
<u>INFC</u>	ORMAT	TION DISCLOSURE STATEMEN	T UNDER 37 CFR §§ 1.56, 1.97 and 1.98			
P.O. 1	30x 145	or for Patents 0 VA 22313-1450				
	This ii .98 as fc		de in accordance with 37 C.F.R. §§ 1.56, 1.97			
<u>Timir</u>	ig and F	ees				
$\boxtimes$		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing da under § 1.53(d);	te of a national application other than a CPA			
		within three months of the actual application; OR	filing date of the national phase of a PCT			
	$\boxtimes$	before the mailing of a first substan RCE).	tive office action (including after filing of ar			
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:					
		a final rejection under 37 C.F.R. 1. termination of prosecution, e.g. Ex	113; Parte Ouayle, M.P.E.P § 609(B)(2); OR			

a notice of allowance under 37 C.F.R. § 1.311; and

		is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:		
		a final	action under 37 C.F.R. § 1.113;		
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
OR		OR a r	notice of allowance under 37 C.F.R. § 1.311;		
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:		
	the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee \$180.00 under 37 C.F.R. § 1.17(p).				
Statem	nents Ur	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited 1	Materia	<u>ls</u>			
		Copies of materials listed but not attached were cited in benefit (35 U.S ancestor application Serial No. <u>11/637,810</u> , on Form 892 by the Exami Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
		Copies	s of materials listed but not attached were cited in an international search		

		report dated		
		Not required by 37 CFR § 1.98.		
		Copies of the materials listed are attached (except for the foregoing).		
Non-E	English I	Language References		
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).		
		A foreign-language search report from a foreign patent office is provided, a pertinent parts are translated substantively below:		
		<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> <li>Translation of other relevant information on foreign search report</li> </ul>		
<u>Other</u>	<u>Informa</u>	<u>ution</u>		
<u>Payme</u>	ent of Fe	ees Due (If Any):		
	A check for \$ covering the fee identified above is attached.			
	Payment by credit card via EFS for \$ covering the fee identified above.			
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

raesinine. (703) 243-0410

Attorney Docket No.: ELLIS-0002-P02-C01

Date: September 29, 2009

AJZ:dap